Funding
=======

This work was supported by Arthritis Research UK Primary Care Centre and the Department of Medicines Management, Keele University. Richard A Hayward is receiving an In-Practice Fellowship from the National Institute for Health Research

Background
==========

The reported prevalence of insomnia in the general population is high, varying between 6% and 37% depending on the criteria used. Insomnia may be defined as simply self-reported \"difficulty sleeping\" on one or more nights in the previous month or more stringently using, for example, the DSM-IV criteria of primary insomnia which excludes insomnia associated with psychiatric or physical illness \[[@B1]-[@B8]\]. Insomnia is a common accompaniment to anxiety and depression, with around two-thirds of those with insomnia reporting anxiety or depression and it may be an early symptom of depression \[[@B6]-[@B10]\]. This link with psychological distress may be one reason for the high health care use in people with insomnia, an increased number of accidents at work, presence of comorbidity and greater use of medication than good sleepers \[[@B7],[@B11],[@B12]\].

Most studies of insomnia are cross-sectional, hence the natural history of insomnia is not fully explored. There are several studies which have examined the outcome in primary care for people presenting with insomnia, and in particular how this relates to management. Foley et al. observed a persistence of insomnia symptoms of 52% in elderly patients in the community over a three year period, persistence being significantly and independently associated with physical disability, depression and sedative use \[[@B13]\]. Janson et al. in a 10 year prospective study of adult men in the community reported associations of insomnia with medical and psychiatric disorders, remission being related to weight loss and smoking cessation; however medication use was not reported \[[@B4]\]. Simon et al. in a community study with a 3 month telephone follow-up likewise found a positive association between insomnia and healthcare use, although this appears to have been closely linked to depression \[[@B14]\].

There are a plethora of treatments available to primary care clinicians for the management of patients with insomnia, both pharmacological and non-pharmacological. This may bear testament to the fact that no treatment is both effective and without side effects, although cognitive behavioural therapy and the melatonin agonist ramelteon appear promising \[[@B7],[@B8],[@B15]-[@B18]\]. Improvements in insomnia following CBT interventions delivered over the internet persisted at 6 month follow-up \[[@B18]\].

We previously reported results from a baseline health survey, linked to medical record review, of health care use for insomnia and mood problems \[[@B9]\]. Of those reporting insomnia at baseline, 30% had either a consultation for a mood disorder or a prescription during the following 12 months, with 21% receiving antidepressants and 8% receiving hypnotics.

This study aimed to use a 12 month follow-up survey of this population to determine the relationship of prescribed medication and consultations for insomnia or anxiety and depression with persistence of self-reported insomnia symptoms.

Methods
=======

This was a prospective cohort study linking baseline and 12 month survey to medical record review \[[@B1]\]. Ethical approval for the study was granted by the North Staffordshire Local Research Ethics Committee. Random selection of patients aged 18 plus was made by computer from the registered populations of five general practices in the UK. More than 95% of the UK population are registered with a general practice, which provides a convenient sampling frame of the general population in a locality. One thousand patients from each practice (a total of 5000 patients) were selected. 115 people were excluded as they were currently in hospital, recently died, left the practice, or were excluded by their GP as suffering from severe mental illness. 4885 questionnaires were therefore sent out in April 2000 with a follow-up questionnaire 1 year later. This study was carried out to investigate headaches and general health, but included questions about sleep, which we have used as a basis for this new investigation.

Jenkins et al. have developed four questions related to insomnia and these were included in both baseline and one year follow-up questionnaires \[[@B19]\]. These were:- \"Over the last month did you i) Have trouble falling asleep, ii) Wake up several times a night, iii) Have trouble staying asleep, iv) Wake up after your usual amount of sleep feeling tired and worn out\'?\". Possible responses were \'Not at all, On some nights, On most nights\'. Our main definition of insomnia was based on answering one or more of these questions\"on most nights\".

The Hospital Anxiety and Depression Scale (HADS) was used to assess anxiety and depression \[[@B20],[@B21]\]. Respondents who scored 8 or over on either of the two domains were classified as having self-reported anxiety or depression.

Pain is closely associated with insomnia, and is likely to be a confounder between poor sleep and the use of primary health care \[[@B22]\]. The participants were asked to shade in on a diagram of a blank body manikin any aches or pains lasting for 1 day or more in the previous month. Number of pain sites was categorised into 0, 1-3 and 4-7 sites.

Consent to examine their medical records was sought from people in the survey population. For the 1 year between the baseline and follow-up questionnaires, relevant consultations and prescription data for mood disorders were extracted. These were defined as either insomnia, or anxiety or depression recorded as the presenting problem, or prescriptions in the groups listed below. Prescription medication data was extracted from the records by British National Formulary categories (BNF) 4.1 and 4.3. All antidepressants (BNF 4.3), including tricyclics and serotonin reuptake inhibitors may be used in the treatment of insomnia, whereas hypnotics (BNF 4.1.1) and anxiolytics (BNF 4.1.2) have different clinical applications. Anxiolytics such as diazepam, chlordiazepoxide and lorazepam were little used in the treatment of insomnia in this group. Categories 4.1.3 (barbiturates) and 4.3.2 (monoamine oxidase inhibitors) had not been prescribed to these patients. The hypnotics (BNF 4.1.1), include the benzodiazepine receptor agonists zopiclone, zolpidem, zaleplon, shorter acting benzodiazepines, temazepam and lometazepam and the longer acting nitrazepam and flurazepam.

Analysis
--------

Respondents to the baseline questionnaire who answered positively to any of the insomnia questions on \"most nights\" were investigated for their use of healthcare over the next year and analysed as regards to their responses to the insomnia questions in the follow-up questionnaire.

The association of any self-reported insomnia symptom at follow-up with relevant health care use for mood disorder was determined after adjustment for self reported baseline anxiety and depression, age, gender, number of insomnia symptoms and number of pain areas. The analysis was repeated for the four individual insomnia symptoms. Analysis was performed using logistic regression with results presented as odds ratios and 95% confidence intervals. SPSS 15.0 for Windows was used.

Results
=======

A flow diagram of participants is given in Figure [1](#F1){ref-type="fig"}. Of the 4885 questionnaires sent out, 2662 were returned at baseline. Following adjustment for deaths and change of address the response rate was 56%. Response was higher in females (61% compared to 51% in males) and in older age groups (65% in those aged 65+ compared to 43% in those aged 18-35). 2363 answered all the sleep questions and of these 2192 consented to examination of their medical records. Of the 2192 responders, 735 reported an insomnia symptom at baseline. Of these, 474 (64%) consented to follow-up at 12 months, returned a follow-up questionnaire and completed the follow-up insomnia questions.

![**Flow diagram of participants**.](1471-2296-13-8-1){#F1}

Compared to those reporting insomnia at baseline who did not consent to record review or did not complete the questionnaire at follow-up, the 474 participants who were followed up were no different in terms of gender (female: 63% v. 60%), age (mean 52 v. 51), levels of anxiety or depression at baseline (68% v. 70%), or reporting multiple pains at baseline (pain in more than 4 sites: 52% v. 47%). When further compared with those who reported insomnia at baseline and consented to record review but did not complete the follow-up questionnaire, in the 12 months after baseline the 474 participants had a similar prevalence of consultation for a mood disorder (18% v. 20%) and hypnotic prescription (8% v. 8%), but slightly lower level in terms of anti-depressant prescription (19% v. 23%).

Persistence of any insomnia symptom
-----------------------------------

327 (69%) of the 474 participants continued to suffer from an insomnia symptom at follow-up. Of the 343 who had no consultation or prescription for a mood disorder during the one year follow-up period, 227 (66%) still had insomnia at 12 months. Of the remaining 131 who had consulted or been given a prescription for a mood disorder, 100 (76%) still had insomnia at 12 months. In the unadjusted analysis, any consultation or prescription for mood disorder was associated with persistence of insomnia problems (OR 1.65; 95% CI 1.04, 2.61) although this association was reduced after adjustment for age, gender, pain, anxiety or depression, and number of symptoms (OR 1.37; 95% CI 0.83, 2.27). Baseline anxiety and depression had a similar level of association as consultation or prescription had with persistence of insomnia problems (OR 1.39; 95% CI 0.87, 2.22).

Prescriptions for hypnotics were strongly associated with persistence of insomnia in the unadjusted analysis with 33 (92%) of those receiving a hypnotic still having insomnia at 12 months (OR 5.38; 95% CI 1.63,17.86). This association was still strong although not statistically significant after adjustment (OR 3.18; 95% CI 0.93, 10.92). There was no association of persistent insomnia with antidepressants. (Table [1](#T1){ref-type="table"})

###### 

Reporting of insomnia at 12 months by health care use in those who self-reported insomnia at baseline

                                     Reported Insomnia 12 months                                  
  ---------------------- ----------- ----------------------------- --------- -------------------- --------------------
                         **Total**   **Yes**                       **No**    **OR^a^**            **OR^b^**
                                     ***n*(%)**                    ***n***                        
                                                                                                  
  Hypnotics                                                                                       
   No                    438         294 (67)                      144       1.00                 1.00
    Yes                  36          33 (92)                       3         5.38 (1.63, 17.86)   3.18 (0.93, 10.92)
                                                                                                  
  Any antidepressant                                                                              
   No                    383         260 (68)                      123       1.00                 1.00
   Yes                   91          67 (74)                       24        1.32 (0.79, 2.21)    1.12 (0.64, 1.96)
                                                                                                  
  Any mood                                                                                        
   consultation No       343         227 (66)                      116       1.00                 1.00
   or prescription Yes   131         100 (76)                      31        1.65 (1.04, 2.61)    1.37 (0.83, 2.27)

^a^unadjusted

^b^adjusted for age, gender, number of insomnia symptoms, pain, anxiety or depression at baseline

Persistence of individual symptoms
----------------------------------

In those reporting \"trouble falling asleep\" at baseline, having a consultation or prescription for a mood disorder was suggestive of higher rates of persistence of this symptom at 12 months although the association was not statistically significant (adjusted OR 1.98; 95% CI 0.98, 4.02). A similar finding occurred for the symptom \"trouble staying asleep\" (adjusted OR 1.78; 95% CI 0.93, 3.43). There was little apparent relationship of persistence with health care use for either of the other two symptoms: waking up several times or waking up tired and worn out. (Table [2](#T2){ref-type="table"})

###### 

Reporting of individual insomnia symptoms at 12 months by health care use in those who self-reported insomnia at baseline

  ----------------------------------------------------------------------------------------------------------------------------------------------------
                                                                       Reported Insomnia 12 months                                 
  ---------------------------- --------------------------- ----------- ----------------------------- --------- ------------------- -------------------
                                                           **Total**   **Yes**                       **No**    **OR^a^**           **OR^b^**

                                                                       ***n*(%)**                    ***n***                       

                                                                                                                                   

  Trouble falling asleep       Any mood consultation No\   97\         51 (53)\                      46\       1.00\               1.00\
                               or prescription Yes         66          46 (70)                       20        2.08 (1.07, 4.01)   1.98 (0.98, 4.02)

                                                                                                                                   

  Wake up several times        Any mood consultation No\   269\        177 (66)\                     92\       1.00\               1.00\
                               or prescription Yes         110         70 (64)                       40        0.91 (0.57, 1.44)   0.78 (0.46, 1.32)

                                                                                                                                   

  Trouble staying asleep       Any mood consultation No\   167\        92 (55)\                      75\       1.00\               1.00\
                               or prescription Yes         74          53 (72)                       21        2.06 (1.14, 3.71)   1.78 (0.93, 3.43)

                                                                                                                                   

  Wake up tired and worn out   Any mood consultation No\   177\        93 (53)\                      84\       1.00\               1.00\
                               or prescription Yes         89          55 (62)                       34        1.46 (0.87, 2.46)   1.36 (0.77, 2.42)
  ----------------------------------------------------------------------------------------------------------------------------------------------------

^a^unadjusted

^b^adjusted for age, gender, pain, number of insomnia symptoms, anxiety and depression at baseline

Discussion
==========

This study linked baseline and 12 month postal surveys in a general population sample with primary care medical records. Those receiving primary care for mood disorders did not have better outcomes in terms of remission of their insomnia symptoms. In those reporting insomnia at baseline, three-quarters of those receiving health care management still had symptoms at follow-up.

This study found persistent insomnia symptoms were higher in people prescribed hypnotic drugs, but there was no association with antidepressant use. Foley et al. also found a close relationship between sedative medication and persistence of insomnia symptoms over 3 years in an elderly population in the community \[[@B13]\]. In elderly women (aged 70-75 yrs) Byles et al. found that over 75% of those taking hypnotics at baseline continued to take these drugs at follow-up 4 years later \[[@B23]\] Belleville et al. found that withdrawal of hypnotics over an 8 week period in a group of chronic users of this medication resulted in over 68% of participants in the study being drug free, and 51% still being drug free at 6 months. This was independent of whether or not the tapering dose of hypnotics was combined with self-help CBT in the form of a graded program of literature \[[@B24]\]. Tom et al. in their cohort of middle aged women studied over six years found that persistence of insomnia was related both to psychiatric and physical symptoms and a past history of insomnia \[[@B25]\].

Regardless of primary care use, two-thirds of this sample still had insomnia symptoms at follow-up. This suggests that in most people with insomnia symptoms in the community these symptoms are chronic. The majority did not consult or have a prescription for this problem, some possibly choosing to self medicate. Our previous work showed a clear link between insomnia and depression, this non-consulting group may have unmet need such as depression \[[@B9]\]. Alternatively they may see that primary care is routinely only offering drug treatments with possible side effects. Horne, for example, suggests that some people perceive medication negatively as unnatural or dangerous and prefer to self-medicate \[[@B26]\]. Included in this group will also be some with milder symptoms.

Remission is seen in one-third of people with insomnia at baseline who do not have a consultation or prescription. This no doubt represents the temporary nature of the insomnia stimulus in some but is broadly in agreement with Foley et al. who found a 48% remission of insomnia after 3 years in the community on no sedative medication, decreasing to 33-37% at follow-up when sedative medication was taken \[[@B13]\]. Janson et al. found a remission rate of 65% in men aged 30-69 yrs after a 10 year follow-up, associated with smoking cessation and weight loss, although medication use was not recorded \[[@B4]\]. Even in the more severe insomniacs found in a sleep medicine clinic in the US, Rosenthal et al. (2008), reported the remission of insomnia over 3 to 5 years to be 26% \[[@B27]\]. In Morin et al\'s general population study of those complaining of poor sleep, 31% had what was described as insomnia syndrome, which included those who were dissatisfied with sleep and having insomnia for 3 nights a week for at least a month or those who took hypnotics. At 3 year follow-up 30% of the insomnia syndrome group had persistence of their symptoms and only 8% of this group had spontaneous remission \[[@B28]\].

Hypnotic use appears associated with an increased likelihood of persistence. There are several interpretations of this result. Hypnotic medication may be ineffective in the long-term in primary care and potentially exacerbates the problem, this exacerbation may be due to a specific problem of tolerance and addiction related to both persistence and medication use \[[@B29]\]. The group of people with insomnia who receive prescriptions for hypnotics may in some way be \"different\" to people who do not take hypnotics or do not consult primary care, in ways which might explain poor outcome despite medication.

Whatever the explanation, however, primary care is having little impact on community levels of chronic insomnia with its current range or style of medications. However cognitive behavioural therapy (CBT) may be as effective and with less side effects than medication \[[@B30]\]. Internet-based CBT may be attractive in that it is a low-cost alternative to face to face CBT \[[@B18]\]. The GP may wish first to give sleep hygiene advice or organise CBT if this is available when faced with a patient with complaints of insomnia.

A strength of this study is its longitudinal design with surveys at baseline and 12 months linked by consultation and prescription data. Associations were adjusted for age, gender, and number of pain areas, all of which have been shown to be related to both insomnia and health care use \[[@B12]\]. Existence of other chronic illnesses, for example cardiac, respiratory disease or diabetes, were not measured and may be associated with insomnia and hence may have an influence on the results \[[@B31]\]. We did not measure over the counter medication which may have been used to self-treat insomnia. Response at baseline was 56% and there were some age and gender differences in response. As with all cohort studies, there was further attrition at follow-up. However, there were few differences between those completing follow-up questionnaires and those who did not in demographics, self-reported anxiety or depression, self-reported pain, or health care use for a mood disorder. Whilst any selective non-response may affect the overall estimates of rates of consultation and prescription, it is unlikely to affect the associations found.

Consultation data for mood problems and prescriptions for hypnotics and antidepressants were examined for 1 year between the questionnaires at baseline and follow-up, so it was not possible to ascertain whether health care use was new or ongoing. The study was set in North Staffordshire, UK, an area more deprived than the UK average. However data were collected from five general practices which should reduce the likelihood that health care use was influenced by unusual practice characteristics.

Conclusions
===========

Those with insomnia symptoms continue to have problems regardless of whether they receive primary care management or not. Hypnotic use appears to be related to persistence of insomnia. Further research is needed to determine the most effective methods of identifying and managing insomnia in primary care. There is also a large group of people with persistent insomnia who do not seek primary health care. The reasons for this need to be established as they may have unmet need such as depression and may benefit from seeking primary health care.
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